Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 3, 2000, Pages 752-755

  Gatti, Giorgio ^a,d   Vigano, Alessandra ^b   Sala, Natascia ^b   Vella, Stefano ^c   Bassetti, Matteo ^a   Bassetti, Dante ^a   Principi, Nicola ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; INDINAVIR; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; CHILD; CLINICAL ARTICLE; DEMOGRAPHY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESEARCH; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MALE; NEPHROTOXICITY; PRIORITY JOURNAL;

ADOLESCENT; ANTI-HIV AGENTS; AREA UNDER CURVE; BODY SURFACE AREA; CD4 LYMPHOCYTE COUNT; CHILD; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; LAMIVUDINE; MALE; STAVUDINE; VIRAL LOAD;

EID: 0034001863     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.3.752-755.2000     Document Type: Article

References (11)

1. Carpenter, C. C. J., M. A. Fischl, S. M. Hammer, M. S. Hirsch, D. M. Jacobsen, D. A. Katzestenstein, J. S. G. Montaner, D. D. Richman, M. S. Saag, R. T. Schooley, M. A. Thompson, S. Vella, P. G. Yeni, and P. A. Volberding. 1997. Antiretroviral therapy for HIV infection in 1996. Updated recommendations of the International AIDS Society-USA panel. JAMA 277:1962-1969.
2. Dieleman, J., I. C. Gyssens, M. E. M. van der Ende, S. de Marie, and D. M. Burger. 1999. Urologic complaints in relation to indinavir plasma concentrations in HIV-infectcd patients. AIDS 13:473-478.
3. Dorsey, B. D., R. B. Levin, S. L. McDaniel, J. P. Vacca, J. P. Guare, P. L. Darke, J. A. Zugay, E. A. Emini, W. A. Schleif, J. C. Quintero, J. H. Lin, I. W. Chen, M. K. Holoway, P. Fitzgerald, M. G. Axel, D. Ostovic, P. S. Anderson, and J. R. Huff. 1994. L-735524: the design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. 37:3443-3451.
4. Gatti, G., A. Di Biagio, R. Casazza, R. M. Bassetti, M. Cruciani, S. Vella, and D. Bassetti. 1999. The relationship of ritonavir plasma levels and side effects: implications for therapeutic drug monitoring. AIDS. 13:2083-2089.
5. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics, 2nd ed. Marcel Dekker, Inc., New York, N.Y.
6. Kline, M. W., C. V. Fletcher, A. T. Harris, K. D. Evans, R. C. Brundage, R. P. Remmel, N. R. Calles, S. B. Kirkpatrick, and C. Simon. 1998. A pilot study of combination therapy with indinavir, stavudine (D4T), and didanosine (DDI) in children infected with the human immunodeficiency virus. J. Pediatr. 132:543-546.
7. Melvin, A. J., K. M. Mohan, L. A. Manns Arcuino, R. E. Edelstein, and L. M. Frenkel. 1997. Clinical, virologie and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors. Pediatr. Infect. Dis. J. 16:968-974.
8. Merck Sharp & Dohme. 1998. Indinavir: technical informations. Merck Sharp & Dohme. West Point, Pa.
9. Monpoux, F., N. Sirvent, J. Cottalorda, R. Mariani, and J. C. Lefbvre. 1997. Stavudine, lamivudine and indinavir in children with advanced HIV-1 infection: preliminary experience. AIDS 11:1523-1525.
10. Rutstein, R. M., A. Feingold, D. Meislich, B. Word, and B. Rudy. 1997. Protease inhibitor therapy in children with perinatally acquired HIV infection. AIDS 11:F107-F111.
11. Stein, D. S., D. G. Fish, J. A. Bilello, S. L. Preston, G. L. Martineau, and G. L. Drusano. 1996. A 24-week pen-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 10:485-492.